[Changes in bone density in hemodialysed women treated with transdermal hormone replacement therapy].
OBJECTIVE
Renal insufficiency in women can cause menstrual disturbances and changes of hormonal profile leading to the decrease of bone mass density. Drug administration during dialysis also influences the bone density and increases the risk of osteoporosis. The aim of the study is to assess the effect of transdermal hormonal replacement therapy (HRT) in hemodialysed patients with secondary amenorrhea on bone density.


METHODS
10 women aged from 22 to 45 years old were enrolled in the study. They received 17 beta-estradiol and norethisterone acetate in patches during 12 cycles. Densitometer of lumbar spine and serum estradiol concentration were measured before and after 12 cycles of therapy.


RESULTS
The recurrence of regular vaginal bleeding, the increase of estradiol levels and bone mass density rate about 6% were observed.


CONCLUSIONS
Transdermal hormonal replacement therapy in hemodialysed women with secondary amenorrhea revealed the efficacy of the treatment and prevention from osteoporosis.
Radowicki
Stanisław
S
Kliniki Endokrynologii Ginekologicznej AM w Warszawie.
Skórzewska
Katarzyna
K
Matuszkiewicz-Rowińska
Joanna
J
D000279:Administration, Cutaneous; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy / Q000209:etiology; D018488:Bone Demineralization, Pathologic / Q000209:etiology / Q000517:prevention & control*; D015519:Bone Density / Q000187:drug effects*; D016022:Case-Control Studies; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage*; D006435:Renal Dialysis / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
D004958:Estradiol; D009640:Norethindrone